The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.
Ages between 40 and 75 years;
Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria;
Disease history over 5 years;
Stable dose of dopamine treatment;
Patients who have previously undergone brain surgery;
Past use of stem cell therapy or participation in stem cell clinical research;
Cognitive impairment;
History of mental disorders;
Sequential
Allogeneic dopaminergic neural precursor cell(NCR201)
DrugBilateral implantation
Incidence and severity of adverse events.
Safety and tolerability
Assessment of changes in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III, in comparison with baseline values.
Minimum score: 0; Maximum score: 132; Higher scores mean a worse outcome.
Assessment of changes in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part I,II,IV, in comparison with baseline values.
Higher scores mean a worse outcome.
Assessment of changes in Hoehn & Yahr scale in comparison with baseline values.
Comprehensive clinical assessment for examining the improvements in Parkinson disease.
Assessment of changes in Hamilton Depression Scale (HAMD)-17 in comparison with baseline values.
Comprehensive clinical assessment for examining the improvements in mental state.
Click on the lead sponsor to view all of their trials.
